Coya Therapeutics, Inc. (COYA) Form 8-K — May 12, 2026
On May 12, 2026, Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, as sales agent, to offer and sell up to $30,000,000 in aggregate gross proceeds of its common stock. The offer and sale of the Placement Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus supplement filed with the Securities and Exchange Commission. The Sales Agreement stipulates that Leerink Partners will use commercially reasonable efforts to sell the Placement Shares in 'at the market' equity offerings, including sales made directly on or through the Nasdaq Capital Market.
Key figures
- Commission
- 3.0%
- Gross Proceeds
- 30,000,000
- Offering Price
- 0
- Shares Offered
- 0
Price after filing
Close on the filing date to close N calendar days later (from $4.29). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.